[
    {
        "utterance": "Matt Bogyo: some intros just so we all know again about what people do. Uh just as a reminder what my background is uh chemistry and specifically um synthesis of mainly optical based probes. We do a little bit of pet and now some ultrasound as well. Um but mainly yeah trying to develop agents that can report on specific biological signatures namely proteolytic signatures is what we do a lot of. Um not we don't do that much metabolite stuff but we we are starting to get interested more in lipid metabolites as well. Um so I I think it's easiest if I just call out people looking around the top of my screen here so maybe start with Molly. I know you're eating sorry. ",
        "annotations": {
            "signal expertise": "Matt explicitly states his own expertise in chemistry and specifically in the synthesis of mainly optical-based probes.",
            "express humor": "Matt makes a humorous comment about Molly eating.",
            "encourage participation": "Matt encourages others to participate by suggesting he will call out people to introduce themselves.",
            "process management": "Matt manages the meeting flow by proposing a method for introductions."
        }
    },
    {
        "utterance": "Jin Zhang: Sorry, sorry. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Matt Bogyo: Okay, let's go to Kevin. Let's let's go to Kevin. ",
        "annotations": {
            "Encourage Participation": "This code applies because Matt Bogyo is inviting Kevin to contribute to the discussion.",
            "Process Management": "This code applies because Matt Bogyo is managing the meeting flow by deciding whose turn it is to speak."
        }
    },
    {
        "utterance": "Jin Zhang: Matt, can I um intervene? Sorry, before everything, um can we uh identify a reporter um uh recorder/reporter from this group? If you have done the job uh previously, you you don't have to do it or uh and um anyone else can we have a volunteer? ",
        "annotations": {
            "ask question": "The speaker requests information about identifying a reporter/recorder from the group.",
            "assign task": "The speaker is asking for a volunteer for the role of reporter/recorder, which implies assigning a task.",
            "process management": "The utterance aims to manage the group's process by ensuring a specific role is filled."
        }
    },
    {
        "utterance": "Kevin Cash: Sure, I can do it. ",
        "annotations": {
            "acknowledge contribution": "Kevin is verbally recognizing and accepting the task offered by Jin Zhang.",
            "supportive response": "Kevin is providing a positive response to Jin Zhang's request."
        }
    },
    {
        "utterance": "Jin Zhang: Great. Thanks, Kevin. And um do you want to uh set up a Google Doc? Would that is is that possible? And then we can sort of do the notes there and then copy and paste. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new idea of using a Google Doc for collaborative note-taking.",
            "process management": "The speaker is managing the group's workflow by suggesting a method for documentation and information sharing.",
            "assign task": "The speaker suggests an action item (setting up a Google Doc) to be completed."
        }
    },
    {
        "utterance": "Kevin Cash: Sure, I can do that. ",
        "annotations": {
            "Supportive response": "Kevin is expressing agreement to take on the task of being a recorder/reporter for the group."
        }
    },
    {
        "utterance": "Jin Zhang: Okay, great. And um if you can share that link and other people can also um add uh additional comments notes to that doc. Uh sorry Matt for introduce the introduction. We probably want to have the reporter sort it out. ",
        "annotations": {
            "supportive response": "The speaker expresses agreement or validation by saying 'Okay, great.'",
            "offer feedback": "The speaker provides a suggestion on how to manage the documentation.",
            "process management": "The speaker is managing the process by suggesting how to handle documentation."
        }
    },
    {
        "utterance": "Matt Bogyo: No, you can. ",
        "annotations": {
            "supportive response": "Matt Bogyo is expressing agreement or validation for Jin Zhang to proceed with his suggestion.",
            "acknowledge contribution": "Matt Bogyo is acknowledging Jin Zhang's suggestion."
        }
    },
    {
        "utterance": "Jin Zhang: And also I wonder if we want to take one minute to write down some thoughts uh about this topic and then because quite often when the intro starts, um you know that naturally go into the the discussion. ",
        "annotations": {
            "propose new idea": "Jin Zhang is introducing a new approach for the group to consider, which is to take a minute to write down thoughts before discussing.",
            "process management": "Jin Zhang is suggesting a method for organizing the discussion, which involves writing down thoughts before diving into the conversation."
        }
    },
    {
        "utterance": "Matt Bogyo: Sure, yeah, you can do it that way. That's fine. ",
        "annotations": {
            "supportive response": "Matt is expressing agreement with Jin's suggestion.",
            "acknowledge contribution": "Matt is acknowledging Jin's suggestion."
        }
    },
    {
        "utterance": "Jin Zhang: Right, sorry. I promise after this I'll let you take over. Okay, maybe we take one minute to write down actually for you know uh past a few sessions we didn't have to go to these notes but just in case um we take you know maybe one minute to write down some thoughts about this topic. Again, um it's about metabolites uh I think there are some suggested topics um can uh metabolic imaging be used diagnostically uh mass spec imaging is leading the way um but can that be used together with other imaging methodologies. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by apologizing and promising to let Matt take over soon.",
            "encourage participation": "The speaker invites the group to write down their thoughts about the topic, encouraging participation.",
            "clarify goal": "The speaker is defining and clarifying the goal or topic of discussion, which is about metabolites and metabolic imaging."
        }
    },
    {
        "utterance": "Jin Zhang: Can aptamers and other probes be developed for this? Uh those are the three um topics uh you know sort of initially posed. Posted. Um so okay, one minute start now. ",
        "annotations": {
            "ask question": "The speaker asks if aptamers and other probes can be developed for this, directly requesting information.",
            "summarize conversation": "The speaker summarizes the topics initially posed, reiterating what has been previously discussed."
        }
    },
    {
        "utterance": "Jin Zhang: All right, I think that's it. Um feel free to refer to that these notes um or um if there's a pause maybe Matt or I will ask you to read from your notes. Uh so Matt, you can take over for the intro now. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by instructing participants to refer to their notes and inviting Matt to take over the introduction."
        }
    },
    {
        "utterance": "Matt Bogyo: Yeah, sure. Um Molly's done eating so we can go back to Molly. ",
        "annotations": {
            "process management": "Matt Bogyo is managing the meeting flow by indicating it's time to move on to the next person, Molly."
        }
    },
    {
        "utterance": "Molly Bright: I know. Coffee's coming. Um yeah, I'm Molly Bright. I'm at Northwestern in Chicago. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges a previous statement.",
            "None": "No additional code seems directly applicable beyond acknowledge contribution"
        }
    },
    {
        "utterance": "Molly Bright: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Kevin Cash: Kevin Cash from Colorado School of Mines and my lab makes nanoparticle based sensors and one of our key applications is measuring oxygen dynamics in a range of microbial and in vivo systems as a proxy for metabolism. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states their own expertise and qualifications related to the task, mentioning their lab's work and their background."
        }
    },
    {
        "utterance": "Kevin Cash: So rather than measuring a wide suite of things, we measure oxygen and say, well, that's a good proxy for what's going on and use that to look at spatial and temporal dynamics. ",
        "annotations": {
            "develop idea": "Kevin is expanding on his lab's approach to measuring oxygen dynamics as a proxy for what's going on metabolically.",
            "signal expertise": "Kevin is explicitly stating his lab's expertise in nanoparticle-based sensors and their application in measuring oxygen dynamics."
        }
    },
    {
        "utterance": "Matt Bogyo: Okay, great. ",
        "annotations": {
            "supportive response": "Expressing agreement or validation for Kevin's contribution.",
            "acknowledge contribution": "Verbally recognizing Kevin's input."
        }
    },
    {
        "utterance": "Matt Bogyo: How about uh Sue? Sue, I guess. ",
        "annotations": {
            "encourage participation": "The speaker is explicitly inviting Sue to contribute her expertise, opinions, or ideas by asking 'How about uh Sue? Sue, I guess.'"
        }
    },
    {
        "utterance": "Seu Sim: Hello. So I'm an assistant professor in chemistry at UC Irvine and I'm a soft matter chemist, meaning I engineer polymers and proteins with living cells. So I'm currently interested in organizing bacterial communities within three dimensional mesh or 3D printed architectures and understand their dynamics and interactions. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states their own expertise or qualifications related to the task, mentioning their position as an assistant professor in chemistry and their specific area of work."
        }
    },
    {
        "utterance": "Seu Sim: Nice to meet you all. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Matt Bogyo: Okay uh Candace. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by transitioning to the next person's introduction."
        }
    },
    {
        "utterance": "Candace Fleischer: Hi, I'm Candace Fleischer at Emory. Uh my lab primarily does in vivo MR spectroscopy and thermometry of the human brain. ",
        "annotations": {
            "signal expertise": "The speaker is explicitly stating her own and her lab's expertise or qualifications related to the task, which is in vivo MR spectroscopy and thermometry of the human brain."
        }
    },
    {
        "utterance": "Matt Bogyo: Uh Alex. ",
        "annotations": {
            "encourage participation": "Matt Bogyo is inviting Alex to contribute or introduce themselves, encouraging participation in the meeting."
        }
    },
    {
        "utterance": "Walsh, Alex: Hi, I'm Alex. I'm at Texas A&M University and I do optical imaging of mostly fluorescence and fluorescence lifetime of NADH and FAD. So those are molecules used in metabolic processes. So we're um able to to image something about metabolism that way. ",
        "annotations": {
            "develop idea": "Alex is elaborating on their work, which involves optical imaging of fluorescence and fluorescence lifetime of specific molecules (NADH and FAD) used in metabolic processes.",
            "signal expertise": "Alex explicitly states their background and expertise in optical imaging, particularly focusing on fluorescence and fluorescence lifetime of molecules used in metabolic processes."
        }
    },
    {
        "utterance": "Matt Bogyo: Uh Allison. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Allison Dennis: Hi, I'm Allison Dennis. I'm at Boston University. I um work on fluorescence sensors and fluorescent imaging contrast agents and one of the things that projects that seems most relevant to this uh discussion is we have some small molecule fret sensors that use allosteric transcription factors to bind and unbind DNA in response to a small molecule being around. So if there were favorite transcription factors for metabolites that would be something we'd be interested in making sensors for for example. ",
        "annotations": {
            "encourage participation": "The speaker encourages participation by asking for information about specific transcription factors."
        }
    },
    {
        "utterance": "Allison Dennis: Thanks. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Matt Bogyo: All right, great. Ping. ",
        "annotations": {
            "supportive response": "The phrase 'All right, great' expresses agreement or validation for the introductions.",
            "process management": "The call to 'Ping' manages the meeting flow by moving to the next participant."
        }
    },
    {
        "utterance": "Ping Wang: Hi, um I'm Ping Wang, um assistant professor in radiology from uh Michigan State. Um I I was trained as interventional radiologist and uh develop uh interest in molecular imaging um of diabetes. Uh so the research work in my lab uh mainly focus on uh using imaging uh matters to track the transplanted uh human islet uh and also the stem cell differentiate islet organoids. Um we also uh work a little bit on the nano drug delivery to the targeting the endogenous beta cells. Uh the imaging modality uh we uh use often uh include uh MRI, uh pet MRI um and uh we use the optical imaging um system all the time. Um now uh we have been studying using um magnetic particle imaging. Uh looking forward to have the um discussions with all of you. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states his own background and expertise in radiology and molecular imaging."
        }
    },
    {
        "utterance": "Matt Bogyo: Great, Catherine. ",
        "annotations": {
            "supportive response": "Matt Bogyo expresses a positive sentiment towards Catherine's introduction, showing agreement and support."
        }
    },
    {
        "utterance": "Katharine White: Hi, I'm Katherine White. I'm an assistant professor at the University of Notre Dame and my lab sits at the interface between chemical biology and and cancer cell biology. We develop new optogenetic tools that allow us to manipulate intracellular pH in single cells in real time. Um and as it relates to the kind of concepts here, we're interested in understanding how pH dynamics affect proteins, pathways, cell behaviors and we have some really interesting data uh linking initial pH changes with with metabolic reprogramming that we would like to better understand the dynamics of of that cross talk. So ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise and her lab's qualifications related to the task, mentioning her position at the University of Notre Dame and her lab's work on optogenetic tools and intracellular pH manipulation."
        }
    },
    {
        "utterance": "Katharine White: Great. ",
        "annotations": {
            "Supportive response": "The utterance 'Great.' is a supportive response as it expresses a positive evaluation of the discussion or introduction process without adding new content."
        }
    },
    {
        "utterance": "Matt Bogyo: Thanks uh Lou. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lu Wei: Hi, I'm Lou. Um um I'm assistant professor of chemistry at Caltech. Um so we work on um broadly vibrational uh spectroscopy and and microscopy uh mostly currently on on stimulate Raman. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states his position as an assistant professor of chemistry at Caltech and mentions his work area, signaling his expertise."
        }
    },
    {
        "utterance": "Lu Wei: Um so we are actually trying to push Rama into a um uh well Raman guided uh spatial metabolomics platform. Um so on a single cell level we're trying to um connect the dots, uh draw the correlation between Rama measurements on both spectroscopy and imaging side to uh single ",
        "annotations": {
            "develop idea": "The speaker is elaborating on their research, specifying the goal of connecting Raman measurements with spectroscopy and imaging on a single-cell level.",
            "signal expertise": "The speaker mentions their work involves 'vibrational spectroscopy and microscopy' and specifically 'stimulate Raman,' indicating their expertise in this area.",
            "clarify goal": "The speaker is stating their research goal, which is to correlate Raman measurements with spectroscopy and imaging on a single-cell level."
        }
    },
    {
        "utterance": "Lu Wei_Caltech: cell transcriptomics, um, uh, and also the mass spec, uh, measurement on the on the bulk level. Um, on the, uh, specially resolved level, we're trying to identify new signatures from Raman and trying to, um, resolve the metabolic control, um, um, um, for disease systems. So, uh, recently we, uh, we're trying to identify, um, the metabolic system abilities during, uh, the development of drug resistance in, uh, melanoma patients. ",
        "annotations": {
            "develop idea": "The speaker is expanding on their research approach, mentioning specific techniques and goals, which indicates development of an existing idea.",
            "signal expertise": "The speaker explicitly mentions their work and techniques, signaling their expertise in the area."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Great. Uh, Lingyan. ",
        "annotations": {
            "Supportive response": "The speaker expresses a positive acknowledgment with 'Great'.",
            "Encourage participation": "The speaker invites the next person, Lingyan, to contribute."
        }
    },
    {
        "utterance": "Lingyan Shi: Hi, um, my name is Lingyan Shi. I'm an assistant professor in UCSD at the bioengineering department. Our my lab is developing optical imaging techniques such as SRS and multifoton fluorescence microscopy. So we have been integrating two imaging modalities together to visualize the metabolic activities in living living organisms. So there are two layers of of imaging approach. One is the label free including the fluorescence multifoton fluorescence for example, we look at the NADH or flavor molecules in the living organism. And another layer is the Raman label free approach that we can visualize those lipids and protein information inside the animals and tissues. And we also want to separate the new molecules, uh newly synthesized molecule from the older endogenous molecules. So we have been also label those metabolites such as using heavy water or deterium labeled glucose amino acids to probe the metabolic activities in the live animals. So uh in that case we can separate those new molecules from the older molecules and uh quantitatively image the metabolic turnover rate for each of the macro molecules in the in the body. And uh very glad to discuss with you all today. Thank you. ",
        "annotations": {
            "signal expertise": "Lingyan Shi explicitly states her position as an assistant professor and describes her lab's work, signaling her expertise in the field.",
            "develop idea": "She elaborates on her lab's research approach, including the development of optical imaging techniques and their applications."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Great. That's a good group. I think we have a lot of people working on metabolites, also tons of different modalities and different approaches to imaging, which so it should be a good discussion. Um, I mean, I guess to kick it off, we could start with the sort of first prompt, which I thought was kind of interesting is the idea of metabolites being a sort of early stage, um, reporter for bigger biological processes. So can they be used for diagnostic purposes and um, maybe that would be a good place to start if people have some ideas about that topic. ",
        "annotations": {
            "propose new idea": "The speaker suggests exploring the idea of metabolites as early-stage reporters for bigger biological processes and their use for diagnostic purposes.",
            "ask question": "The speaker asks if metabolites can be used for diagnostic purposes.",
            "encourage participation": "The speaker invites others to share their ideas on the topic."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: And I might broaden it out a bit to rather than just like measuring the metabolic things directly, do patterns in it change, do um, variability in measurements change, like what other things can we use that might be diagnostically relevant before we see physiological impacts. ",
        "annotations": {
            "ask question": "The speaker is requesting information or ideas about other diagnostically relevant things that can be used before physiological impacts are seen.",
            "develop idea": "The speaker is expanding on a previous idea by suggesting an alternative approach of looking at patterns or variability in measurements instead of directly measuring metabolic things."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Yeah, that actually sort of uh um is related to uh one of the uh things that mentioned by different people. I think in terms of looking at metabolites uh or metabolic processes uh what I guess what are the targets, the variety of different targets that we're we're thinking about. I I guess uh summarizing different, you know, different people's uh intro, uh, you know, we looked at uh newly synthesized metabolites as a sort of a whole class, uh specific species, um, NADPH, NADH, uh or oxygen uh as a proxy or or uh developing specific probes for a very specific metabolite. So uh there these are all possibilities. What are some of the advantages uh and challenges uh of targeting these different things for looking at metabolites and metabolic processes. And as Kevin mentioned, uh perhaps, you know, patterns, uh features of any of those, right? as a you know, class uh or as a individual species could be used for diagnostic purpose. Just to uh throw the question out there. ",
        "annotations": {
            "ask question": "The speaker is requesting information about the advantages and challenges of targeting different metabolites or metabolic processes.",
            "develop idea": "The speaker is building upon previous ideas by suggesting different targets for studying metabolites, such as newly synthesized metabolites, specific species like NADPH, NADH, or oxygen as a proxy."
        }
    },
    {
        "utterance": "Katharine White - Notre Dame: I can talk about if um, yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a very minimal and non-specific response."
        }
    },
    {
        "utterance": "Lingyan Shi: May I may I say something about the newly synthesized one with labeling? ",
        "annotations": {
            "encourage participation": "The speaker is requesting permission to contribute to the discussion, which serves as an invitation for themselves to participate and share their thoughts."
        }
    },
    {
        "utterance": "Lingyan Shi: to break the diffraction limit limitation to have a better spatial resolution. ",
        "annotations": {
            "develop idea": "The utterance expands on the idea of using labeling to improve spatial resolution in imaging, building upon previously discussed concepts."
        }
    },
    {
        "utterance": "Katharine White: Yeah, I just wanted to if I can add on onto that because I think you brought up a lot of really interesting points there. Uh, one of which is this kind of spatial resolution of metabolism and so, you know, a lot of the approaches that we have on the cell biology side in terms of, you know, broad population level metabolomics are not sufficient for a lot of the questions that apparently everyone in this group is is similarly thinking about in terms of the spatial organization in 3D and in a tissue where oxygen gradients, pH gradients, nutrient availability might be very altered and so this this ability to get it at spatial organization of metabolism within a cell, within tissue, within an organism I think is is really important and we need to think about the the needs there and then um, you know, I I think it's fascinating that you want subpixel um information there. That is just blows my mind because we can't even get, you know, reasonable dynamic measurements in a single cell sometimes and so the idea that you could have that kind of of uh resolution is is really interesting to me. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of spatial resolution in metabolism by discussing its importance and the current limitations.",
            "identify gap": "The speaker recognizes the gap in current approaches for studying metabolism, particularly in terms of spatial organization in 3D and in tissues.",
            "supportive response": "The speaker is expressing a positive evaluation of the ideas discussed, showing enthusiasm for the potential of high-resolution metabolic imaging."
        }
    },
    {
        "utterance": "Katharine White: Um, but I think coming this connects also to to Kevin's point about heterogeneity and uh at the, you know, uh what is the variability that we're interested in and and what is the sensitivity that we need in our measurement tool to be uh confident that we're capturing that variability if it's biologically meaningful. ",
        "annotations": {
            "develop idea": "Katharine White is expanding on existing ideas by relating them to her own perspective on spatial resolution and variability in metabolic measurements."
        }
    },
    {
        "utterance": "Katharine White: And as as we come at this problem, we see a lot of these correlations at the population level that we're not able to confirm at a single cell level reliably. And so one of the uh questions that maybe we can kind of jump off of where Kevin uh and Lingyan got us started is, you know, what are the constraints there? What is the what is the need in terms of probes in terms of to make these kind of leaps from maps or measurements to diagnosis to phenotype to um outcome. ",
        "annotations": {
            "develop idea": "The speaker is expanding on previous ideas by discussing the need to understand constraints and requirements for probes to advance in measuring metabolites and metabolic processes.",
            "ask question": "The speaker is requesting information about the constraints and needs in terms of probes for making leaps from maps or measurements to diagnosis, phenotype, and outcome."
        }
    },
    {
        "utterance": "Seu Sim: So I I make polymers. So I something that I wrote down here. I I love the idea of using mass spectrometry to look at the metabolomic processes, but as many of you pointed out, it's a very small scale problem. So we can also imagine using expansion microscopy, but then you have to think of a way to anchor your molecules of interest in a reliable way so that it flies. So have anyone, you know, read anything about it and, you know, any experiences I would love to talk about it. ",
        "annotations": {
            "develop idea": "The speaker expands on existing ideas by suggesting expansion microscopy as an alternative approach to mass spectrometry for looking at metabolomic processes.",
            "ask question": "The speaker asks if anyone has read anything about anchoring molecules for expansion microscopy and if they have any experiences to share."
        }
    },
    {
        "utterance": "Matt Bogyo: So do do people know currently for like what's I mean, I know mass spec is being used as an imaging technique and that's good for small metabolites, but um obviously it has limitations because you have to process samples in a very specific way. Um yeah, I guess the question is, you know, how do you integrate those technologies into something that's a reasonable diagnostic workflow for for like a clinical specimen or are we talking about samples that would be biopsied or where where do you guys see the application in metabolic profiling? ",
        "annotations": {
            "ask question": "The speaker is requesting information on integrating mass spec technologies into a diagnostic workflow for clinical specimens.",
            "develop idea": "The speaker is expanding on the idea of using mass spec for imaging small metabolites and discussing its limitations and potential applications."
        }
    },
    {
        "utterance": "Lingyan Shi: Well, um yes, I think one application is already uh being conducting in hospital with SRS, the stimulated Raman microscopy is to uh really separate those cancer cell from the normal normal tissue. For example, the the brain tumor case. So for the brain tumor removal, the surgeon will just take take out the just open the skull and take out the brain tumor and they usually will do assess on that uh scar wall inside the brain to to see if there's any tumor cell left inside the brain. So the traditional or conventional way is to just take a little very little tiny piece out and do the histology image H and E staining to to check if the cell uh are all brain cells and there's no tumor cells left inside. So then we can close the skull and wake up the patient. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea by providing a concrete example of how SRS can be used in hospitals to separate cancer cells from normal tissue.",
            "offer feedback": "The speaker provides a specific example and explanation of how SRS can be used, offering insight into its application in medical diagnostics."
        }
    },
    {
        "utterance": "Lingyan Shi: But usually it takes the conventional method usually takes too long and uh maybe a few hours so that the patient will be under anesthesia for a few hours waiting for the results. But now um since SRS allow us to visualize the protein and the lipids very rapidly. Well for example I I I take like five minutes to take the image when you have that piece of tissue and immediately you have the digital H and E maybe H and E and the pathologist can look at the H image in a few minutes and determine if there's tumor still left or not. So it saves a few hours and uh the patient can be wake up very soon um not they they don't need to be under anesthesia for that long. So it's kind of protecting the brain. Also it's it's a biopsy. It's a it's a diagnostic biopsy um during the clinical clinical clinical period. So I think that types of like fast rapid diagnostic molecular level determination of based on the imaging technology such as SRS may uh be helpful. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on how SRS can be used for rapid diagnostic purposes, providing specific examples and explanations.",
            "supportive response": "The speaker is providing a positive evaluation of SRS for diagnostic purposes, highlighting its benefits."
        }
    },
    {
        "utterance": "Matt Bogyo: So what other types of modalities do you guys think would be useful? Obviously, so Raman is one, right, that we're just talking about. Are are other people here have expertise in other modalities that could be applied in the sort of clinical setting? And maybe also maybe we could think about some of the limitations to that strategy using Raman or ",
        "annotations": {
            "ask question": "The speaker is asking a question about what other types of modalities could be useful and inviting discussion.",
            "encourage participation": "The speaker is seeking input from others, encouraging them to contribute their thoughts and expertise.",
            "process management": "The utterance helps manage the discussion flow by directing it towards exploring various modalities and their limitations."
        }
    },
    {
        "utterance": "Ping Wang: I I just want to add a little bit to the discussion. Um, for the um, for the first question, um, metabolic change, uh, I mean, use metabolic imaging used for diagnostically. If you include cancer, um, like I mean, as as a disease for for like a cancer metabolic imaging as part of the discussion, I think it's already been widely used. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of using metabolic imaging for diagnostic purposes, specifically mentioning cancer.",
            "supportive response": "The speaker is contributing to the discussion in a supportive manner by adding a relevant point.",
            "clarify goal": "The speaker is contributing to clarifying the goals or directions of the discussion, specifically by mentioning the application of metabolic imaging in cancer diagnostics."
        }
    },
    {
        "utterance": "Ping Wang: I mean, it's a clinical modality. I mean, pet I uh especially for pet like FDG uh F18 FDG, that's widely used every day for the diagnosis. Um, and for another disease I have been working on for diabetes, um, yeah, it's it's closely to the glucose metabolism. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on the idea of using PET scans for diagnostic purposes, providing examples.",
            "signal expertise": "The speaker is implicitly stating their familiarity or expertise with PET scans and their applications in disease diagnosis."
        }
    },
    {
        "utterance": "Ping Wang: Uh so um in terms of diabetes um there's a there's a very big problem for us like for the endogenous beta cell imaging, beta cell mass imaging. That's a very big problem and people trying to solve this problem for 20 years still not successful. Um because of limited uh special resolution and also the sensitivity we use. We have been tried with the MRI mostly and some people tried pet. So that's why people trying to uh combine the pet MRI uh to complement each other to increase the uh sensitivity and the special resolution. Um in creating um like receptor imaging also it's a big big part for the metabolic imaging. Um example for that is the GLP1 glucagon like peptide one. Um that's also related to the beta cell imaging. ",
        "annotations": {
            "develop idea": "The utterance expands on existing ideas by discussing the limitations and potential combinations of imaging methods for beta cell mass imaging.",
            "signal expertise": "Ping Wang mentions their work and experience, signaling their expertise in imaging and diabetes research.",
            "identify gap": "The utterance explicitly mentions limitations in special resolution and sensitivity as significant challenges."
        }
    },
    {
        "utterance": "Ping Wang: I do have another I do have a question for Kevin. to for for my uh experiment. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification from Kevin regarding their experiment."
        }
    },
    {
        "utterance": "Ping Wang (MSU): uh the lack of oxygen, um and lack of the blood supply um is may contributors for this um eyelid organoids uh graphs um loss. ",
        "annotations": {
            "propose new idea": "The speaker suggests that the lack of oxygen and lack of blood supply may be contributors to the loss of eyelid organoids.",
            "develop idea": "The speaker is expanding on previous discussions about challenges in grafting eyelid organoids by suggesting specific factors that could contribute to the loss."
        }
    },
    {
        "utterance": "Ping Wang (MSU): So um if if you can comment on that um like if we can label the cells with some nanoparticles uh you you design synthesize as an indicator uh for the oxygen um I mean level uh in the transplant sites. ",
        "annotations": {
            "ask question": "The utterance is a request for information or comment on using nanoparticles as indicators for oxygen levels in transplant sites.",
            "signal expertise": "The question is directed at Kevin Cash, implying recognition of his expertise in nanoparticle-based sensors."
        }
    },
    {
        "utterance": "Ping Wang (MSU): That's probably uh one I mean application for clinic because you know in clinic for eyelid transplantation for type one diabetes um one recipient usually need two donors, the eyelid from two donors. And uh the clinical data showed nowadays like less than 50% of the recipients um can remain independent uh insulin independence after five years. So ",
        "annotations": {
            "develop idea": "The speaker is elaborating on previous points about potential applications and challenges in clinical settings for eyelid transplantation in type one diabetes.",
            "clarify goal": "The speaker is discussing a specific application and challenge, relating to the objectives of improving outcomes for recipients of eyelid transplantation."
        }
    },
    {
        "utterance": "Ping Wang (MSU): we trying to develop something like uh maintain the function of the eyelid uh graphs. ",
        "annotations": {
            "clarify goal": "The speaker is defining and discussing their objectives, specifically aiming to develop something that maintains the function of the eyelid graphs.",
            "process management": "The speaker is managing the discussion by introducing their research goals and objectives."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: I mean at least for our technology in particular, ",
        "annotations": {
            "None": "The utterance does not explicitly fit into any of the provided categories as it is a prefatory statement rather than a contribution that can be coded."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: it likely wouldn't work because our stuff's all optical. So if it's actually transplanted into a patient, uh it's not optically accessible anymore. ",
        "annotations": {
            "identify gap": "The speaker explicitly states a limitation of their approach, which is that it is not optically accessible when transplanted into a patient.",
            "offer feedback": "The speaker provides specific feedback on why their approach may not work in a certain context, highlighting a limitation.",
            "critical response": "The speaker questions the applicability of their method in a certain context, indicating potential issues."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: But I'm sure there's other oxygen sensitive approaches that would work in that deeper tissue. ",
        "annotations": {
            "offer feedback": "The speaker provides a suggestion for an alternative approach that could work for deeper tissue oxygen sensing.",
            "supportive response": "The speaker's comment is supportive as it suggests an alternative solution rather than dismissing the idea."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: But just the the ones we do are all optical because for us we're doing most of our stuff either near surface or in in vitro model systems. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on their previous statement about their technology, specifying its limitations."
        }
    },
    {
        "utterance": "Ping Wang (MSU): Yeah, some uh developed for the optical imaging can um also can be considered like radio labeled, yeah, for para paramize. ",
        "annotations": {
            "offer feedback": "The speaker provides a suggestion for an alternative approach by mentioning the possibility of radio labeling for optical imaging.",
            "propose new idea": "The speaker introduces a new idea of considering optical imaging techniques that can also be radio-labeled."
        }
    },
    {
        "utterance": "Ping Wang (MSU): Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: So what are some of the, I mean I'm just starting to think do people know I I don't keep up with as much about the metabolism imaging field, but I know like FDG is a big one, right? But that's just that's basically uptake of a reporter molecule by cancer cells. ",
        "annotations": {
            "ask question": "The speaker is requesting information about the metabolism imaging field, specifically about FDG and its application.",
            "encourage participation": "The speaker invites others to contribute their knowledge by asking if they are familiar with the metabolism imaging field."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: But are there other classes of like contrast agents for example that that bind or that are mimics of metabolites and that accumulate much like FDG so that are used in other areas? Seems like that's another area that would be important. ",
        "annotations": {
            "ask question": "The speaker is requesting information about the existence of other classes of contrast agents that bind or mimic metabolites and accumulate like FDG, indicating a need for clarification or expertise from other team members."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Yeah, I can talk briefly about MR spectroscopy, which I'm guessing most of you are familiar with, but it it is a marker of um or it is a method that can measure, you know, quantitative metabolite concentrations localized in whatever region. And it is used in the clinic, cancer is a good example, it's used for um like fatty liver disease. Um, but you do get like basically you get in vivo MR spectra um localized. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the concept of MR spectroscopy, its applications, and how it works, providing more details to the discussion."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: It's also sampling error, right? I mean because you have to know where you want to look, right? ",
        "annotations": {
            "critical response": "The speaker is questioning and highlighting a limitation (sampling error) of the approach being discussed, indicating a challenge with the method."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Yeah, I mean we can do whole brain, you can do multiple regions. I guess um yeah, I mean in a clinical setting you would do a small region of interest. Um so you'd have some information already. Um but I guess in terms of the bigger question of metabolism, you know, um something that is kind of emerging is genetic counseling. So using, you know, gene mutations to predict disease. ",
        "annotations": {
            "develop idea": "The speaker elaborates on the use of MR spectroscopy in clinical settings, discussing its capabilities and limitations.",
            "propose new idea": "The speaker introduces genetic counseling and using gene mutations to predict disease as an emerging area related to metabolism."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): And I guess the idea that I had with metabolic imaging is really, you know, we're not looking at kind of metabolism reprogramming, which we know is really common in cancer, but it's actually probably related to a number of different diseases, diabetes like Ping was saying. And so thinking about the very big picture is, you know, genetics are what we always go to for everything, right? ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by discussing the relation of metabolic imaging to various diseases, including cancer and diabetes, and considering the broader implications involving genetics."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Cancer, do some genetics tests. Um children do some sort of genetic screening, etc, etc. But metabolism is often left out and we know like the prompt is saying, we know that metabolic changes can actually proceed any physiological or structural changes. So from a very big picture, imaging metabolism with maybe in the clinic with the exception of FDG pet and some other tracers from mostly cancer, right? ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea that metabolic changes can precede physiological or structural changes and discussing the implications for clinical practice.",
            "identify gap": "The speaker explicitly identifies a gap in current clinical practice, which is the oversight of metabolism.",
            "clarify goal": "The speaker is discussing the goal of incorporating metabolic imaging into clinical practice."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Um is is pretty absent. And so I think there is a big need for thinking about this on a very large scale in terms of, you know, why is metabolism important? Is it important? How is it important? Um and obviously with something like MRI we're working on a very macroscopic scale like you said, we have large regions. ",
        "annotations": {
            "ask question": "The speaker is asking questions about the importance of metabolism and how it is important, seeking clarification or information.",
            "identify gap": "The speaker notes that metabolic imaging, aside from a few examples, is 'pretty absent,' indicating a recognition of a gap in current practices or understanding."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): So is MRI done like pretty routinely now like for for metabolic imaging in cancer? ",
        "annotations": {
            "ask question": "The speaker is seeking information about the routine use of MRI for metabolic imaging in cancer, indicating a request for clarification or expertise."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Like I mean it does it does seem like it requires a lot of time and instrumentation and cost and other things. I mean are there barriers there? ",
        "annotations": {
            "critical response": "The speaker is questioning the feasibility of using MRI for metabolic imaging due to its high requirements for time, instrumentation, and cost.",
            "ask question": "The speaker is seeking information about potential barriers to using MRI for metabolic imaging."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Um, I mean it it I would say in many clinics it is done routinely. Um it it depends a little on the tumor, but it's the exact same instrumentation and anytime someone has a tumor you would scan them with an MRI anyway. So they're already in the scanner if you allow if your site does spectroscopy, ",
        "annotations": {
            "supportive response": "The speaker validates the routine use of MRI in many clinics."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): it's it's naturally integrated into every MRI whether you use it or not. You you kind of have to pay extra for it when you're buying your system. So if you didn't do that you won't have it. But um even non-academic sites are using spectroscopy for tumors. Um so I wouldn't say it's routine, but I would say for so for example for fatty liver disease it is routine because that's a really great way to quickly sample fat distribution. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on the use of spectroscopy in MRI systems, providing more details about its integration and application.",
            "signal expertise": "The speaker is demonstrating her knowledge about MRI systems and spectroscopy, indicating her expertise in the area.",
            "supportive response": "The speaker is providing a positive evaluation of using spectroscopy for certain applications, like fatty liver disease."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Yeah. Cool. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lu Wei, Caltech: So following up on that, I actually I'm interested to understand some of the technical challenges across different modalities. ",
        "annotations": {
            "ask question": "The speaker is requesting information about the technical challenges across different modalities, seeking clarification or expertise from other team members."
        }
    },
    {
        "utterance": "Lu Wei, Caltech: So for example, Candace you just said uh for MRI um to do metabolic imaging, what are the I mean for from a technical point of view, what are the challenges that limits is for the applications? What are the issues you usually run into? ",
        "annotations": {
            "ask question": "Lu Wei is requesting information about the technical challenges and issues related to MRI for metabolic imaging."
        }
    },
    {
        "utterance": "Lu Wei, Caltech: So for example for us, um I I guess for for for FDG for pet in order to overcome those fast decay, you have to prepare the sample very fast and then you only have a limited window to do the imaging. Um for us for Rama, we have the corresponding uh deuterium version of glucose or alcohol version of glucose that we can image. Uh which worked very well at a relatively longer time scale, um but uh with a shorter time scale, for example on the minutes or uh tens of minutes level where I usually limited by uh the sensitivity. So we don't have we don't have enough molecule accumulated for detection. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on the challenges of using certain imaging modalities, providing specific examples and limitations.",
            "identify gap": "The speaker explicitly mentions a limitation of their approach, specifically the issue of sensitivity at shorter time scales and the inability to detect enough molecules for detection."
        }
    },
    {
        "utterance": "Lu Wei, Caltech: And also um uh I I saw there's a question on um whether there's a aptamer uh based uh probes that could be developed to imaging metabolites. ",
        "annotations": {
            "ask question": "The speaker is requesting information about the development of aptamer-based probes for imaging metabolites."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Great questions. ",
        "annotations": {
            "Supportive response": "Jin Zhang expresses agreement and encouragement without adding new content."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): So do we want to start one you know, do one by one? ",
        "annotations": {
            "process management": "Jin Zhang is suggesting a method for organizing the discussion, specifically asking if they want to start discussing items one by one."
        }
    },
    {
        "utterance": "Lu Wei, Caltech:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): You Candace, you want to um answer uh uh ",
        "annotations": {
            "ask question": "Jin Zhang is asking Candace if she wants to answer a question, indicating a request for information or clarification."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): the question about the the limitation I guess I I also have related the question whether for the MRI metabolic imaging this is looking at fat, right? And uh and uh are there uh you know, you know, limitations what um uh was asking. but in terms of uh expanding it, you know, is there a need for metabolic profiling for looking at um more uh or or more specific species of metabolites and things along that line. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on the limitations of MRI metabolic imaging and the need for metabolic profiling.",
            "develop idea": "The speaker is exploring and expanding on the concept of metabolic profiling and its applications."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): And then I'll come back to the uh buffering problem of a probe based. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Candace Fleischer: um, you know, hydrogen nuclei, which is are present in everything. Um, so I think those are the pros, but it's certainly challenging. And then, you know, on the other side of things, the analysis is difficult. So while there's some inline analysis, so you know, a radiologist can sit at the scanner and see peaks and get approximate idea of patterns. Um, it's not 100% quantitative, it's not standardized across sites. Um, I guess that's those are big medical imaging questions separately even from metabolism is um, are those limitations. ",
        "annotations": {
            "develop idea": "Candace is expanding on the idea of using MRI for metabolic imaging by discussing its pros and cons, specifically highlighting the challenges in analysis and quantification.",
            "identify gap": "She is explicitly pointing out the limitations and challenges of MRI in this context, such as difficulty in analysis, lack of 100% quantification, and issues with standardization across sites."
        }
    },
    {
        "utterance": "Jin Zhang: Well, I guess related to that, there perhaps um, there isn't a need to really look at very, very specific species, right, in that setting. Just uh looking at overall perhaps, you know, phospho phosphorus um or or fat signal, um you don't have to really look at a one particular lipid species. That's my question related to the MRI. ",
        "annotations": {
            "ask question": "The utterance contains a direct question seeking clarification related to MRI.",
            "develop idea": "The speaker is expanding on their thoughts about the necessity of looking at specific species versus overall signals in metabolic imaging with MRI."
        }
    },
    {
        "utterance": "Candace Fleischer: You don't have to, but I would say most people do. ",
        "annotations": {
            "supportive response": "The speaker validates and supports the approach of looking at specific species of metabolites in MRI metabolic imaging.",
            "develop idea": "The speaker elaborates on the common practice in the field regarding metabolic profiling specificity."
        }
    },
    {
        "utterance": "Jin Zhang: Sorry. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Candace Fleischer: I said you don't have to, but most people do. So, for example, in tumors, um, you know, for Raman biopsy is one example, but we can also do that with MR spectroscopy and see the boundary of the tumor and actually we're using that in our clinic to guide radiation therapy. ",
        "annotations": {
            "develop idea": "The speaker provides a concrete example of using MR spectroscopy to guide radiation therapy, building on existing ideas.",
            "acknowledge contribution": "The speaker references Raman biopsy as another method, showing an alternative approach."
        }
    },
    {
        "utterance": "Candace Fleischer: Um so we can take an image and see areas that were weren't resected given metabolic ratios in the brain and then we can target those regions. Um, so you you're right, you certainly don't have to. It can be untarget kind of an untarget metabolomics approach. ",
        "annotations": {
            "develop idea": "The speaker expands on the idea of using metabolic ratios for imaging and targeting regions in the brain.",
            "supportive response": "The speaker agrees with a previous statement, acknowledging that the approach can be untargeted.",
            "offer feedback": "The speaker provides an alternative approach, suggesting an untargeted metabolomics approach."
        }
    },
    {
        "utterance": "Candace Fleischer: . ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang: So come back coming back to um, Lou's question about the uh uh is it Lou or Way? Sorry. ",
        "annotations": {
            "final answer": {
                "acknowledge contribution": "Jin Zhang is verbally recognizing Lou's (or Way's) question, showing that they are considering and will address it."
            }
        }
    },
    {
        "utterance": "Lu Wei: Lou, Lou. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lu Wei: Unmuted. It's Lou, yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang: Lou, okay. Lou's question about um the uh um buffering effect. ",
        "annotations": {
            "acknowledge contribution": "Jin Zhang is verbally recognizing Lou's input, specifically Lou's question about the buffering effect."
        }
    },
    {
        "utterance": "Jin Zhang: Um so this you know, of course uh if we design optical probe or or some of the other probes to to um bind to a specific molecule or uh you know, replace that endogenous molecule with a labeled molecule. Uh there there's uh you know, unwanted effect um uh like a buffering effect uh or or perturbation effect. But I guess the idea is um if you can really enhance the sensitivity and to, you know, to use that as a tracer, right? That's kind of the the pet um imaging that's what the based on, you know, you can really enhance the sensitivity lower the the amount of labeling. ",
        "annotations": {
            "code name": "Clarify goal",
            "explanation": "The speaker discusses the goal of enhancing sensitivity for imaging purposes."
        }
    },
    {
        "utterance": "Jin Zhang: Then you're uh going to the the sweet spot of um be able to detect something but not perturbing that much. Anyone want to chime in? I think Axon develop probes for uh along this line. Sorry, Sue was going to say something. ",
        "annotations": {
            "encourage participation": "The speaker invites others to contribute to the discussion.",
            "develop idea": "The speaker mentions a related example or work to expand the discussion."
        }
    },
    {
        "utterance": "Seu Sim: Oh, I was actually thinking in this domain. I I like the idea of aptamer based, but I also like the idea of like not just a binding event, something that's amplifiable so that we bring like the low concentration of metabolite into readable range. So in the spirit of lowest possible perturbation and something that's amplifiable, not just, oh, it it's bound to like A bound to B and that's definitely not going to be easy to detect. So I don't know if it's possible, but if we can think of it a way to, you know, bring this aptamer or nucleic acid based binding event and lead that into some amplification event so that we have dynamic range to read out rare metabolite that could be of interest can be an interesting direction. ",
        "annotations": {
            "propose new idea": "The speaker introduces a novel approach of using aptamer-based methods combined with amplification events for detecting metabolites.",
            "develop idea": "The speaker elaborates on the concept by discussing the need for amplification to detect low concentrations of metabolites with minimal perturbation."
        }
    },
    {
        "utterance": "Jin Zhang: Actually kind of contrary to the idea of having the amplification. ",
        "annotations": {
            "critical response": "The speaker is questioning or providing a contrasting view to the idea of having amplification for detecting metabolites."
        }
    },
    {
        "utterance": "Allison Dennis: I go back and forth on whether it's better to have or it's just application dependent, whether it's better to have that one snapshot with the amplification of signal, but then it's an an irreversible signal, right? You're always only increasing never, you know, playing with the the kinetics to have unbinding of the metabolite that you're you're sensing and and bringing the signal back down. So, you know, depending on the the uh dynamics of what the the molecule that you're trying to sense, it could be that you want that accumulation of signal um just to see it at all or you might want a a reversible signal so that you see the the uptick and then the the decline of the reduction in the concentration of that metabolite um in response to something. Just a a totally different design um for the two outcomes. ",
        "annotations": {
            "signal expertise": "The speaker discusses specific considerations and trade-offs in probe design for metabolic imaging, indicating her expertise.",
            "develop idea": "The speaker elaborates on the idea of using probes for sensing metabolites, discussing different design considerations.",
            "supportive response": "The speaker provides a thoughtful and supportive contribution to the discussion, acknowledging different approaches."
        }
    },
    {
        "utterance": "Jin Zhang: Yeah, but perhaps for for different applications, uh that could, you know, the the different uh focuses or strategies. But I guess in principle, it is possible to build some amplification not for the binding part of it. ",
        "annotations": {
            "code name": "develop idea",
            "explanation": "Jin Zhang is expanding on existing ideas about different applications and strategies for metabolic imaging and probe development."
        }
    },
    {
        "utterance": "Jin Zhang: Well, some simple applica amplification that you that's used by people in the field. Of course, there's enzymatic um amplification and um uh and there's transcriptional uh based. I think Andrew put it in the in the chat, ribo switch. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and adding information to the discussion.",
            "acknowledge contribution": "The speaker mentions Andrew's contribution in the chat, acknowledging his input."
        }
    },
    {
        "utterance": "Andrew Feig: Yeah, so consider um you might want to look at some of the systems that have been developed by the synthetic biology community, the gem circuits where you can they actually have modular circuits that are integrators for instance and uh that do uh uh timed phase as well. ",
        "annotations": {
            "propose new idea": "The speaker proposes considering systems developed by the synthetic biology community, specifically mentioning 'gem circuits', as a potential approach for addressing challenges in metabolic imaging or analysis.",
            "develop idea": "The speaker elaborates on the proposed idea by mentioning specific features of 'gem circuits', such as modular circuits that are integrators and that do timed phases."
        }
    },
    {
        "utterance": "Andrew Feig: Well, so there there are a whole bunch of these that have been developed with uh different logics on circuits. ",
        "annotations": {
            "supportive response": "Andrew Feig is providing information in a supportive manner about the existence of developed systems with different logics on circuits, which could be relevant for the discussion on metabolic imaging technologies."
        }
    },
    {
        "utterance": "Seu Sim: Right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges a prior statement with a minimal 'Yeah.'"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "The utterance does not contain enough information to apply any specific code."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "acknowledge contribution": "The speaker is acknowledging a prior statement or contribution from another group member."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it's a minimal response."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "Acknowledge contribution": "The speaker is acknowledging a prior statement.",
            "Supportive response": "The speaker is expressing agreement or support."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a minimal response without additional context or content."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Candace Fleischer: products. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang: Great. Um, I wonder if Alex or Molly want to chime in for any of the topics, look at your notes. ",
        "annotations": {
            "encourage participation": "Jin Zhang invites Alex and Molly to contribute their thoughts on the topics being discussed, encouraging their participation."
        }
    },
    {
        "utterance": "Molly Bright: And mainly I'm a little distracted. Sorry guys. Um, the yeah, I I'd say that with my type of MRI, we um, we say we want metabolism, but what we typically are saying is we want neural activity. And that's such a different thing and yet we say it and and that's sort of a mindset issue. Um, the other thing is out of the prompts that we started with, the idea that metabolic changes proceed physiological changes, I think when we're looking at the brain and and we are using physiological measures of um, well what I would call physiological measures, we're using vascular properties to estimate a metabolic property. So the timeline of things is really important when we try to infer one from the other. So in the pathologies, knowing when we can trust our models of how vascular signals relate to metabolism or when those models have already broken down because metabolism wrecked that something about the vascular thing we're measuring. I'm not sure I'm being very coherent, but I feel like it's it's a big challenge that like with a lot of things with this neuro MRI view of metabolism, I feel like we're we're a bit superficial with it so far. ",
        "annotations": {
            "develop idea": "Molly expands on the concepts of metabolism and physiological changes, relating them to her work with MRI.",
            "signal expertise": "Molly mentions her experience with a specific type of MRI, indicating her expertise in the field.",
            "identify gap": "Molly points out a challenge in the field, specifically the superficiality of the neuro MRI view of metabolism.",
            "critical response": "Molly critiques the current approach, suggesting that it may be superficial."
        }
    },
    {
        "utterance": "Molly Bright: Well metabolism, not MRS. I am not doing spectroscopy. ",
        "annotations": {
            "signal expertise": "Molly is explicitly stating her own area of work and what she is not doing, which can be seen as signaling her expertise and boundaries within the discussion.",
            "None": "No other code directly applies to this utterance as it does not propose a new idea, ask a question, provide support or criticism, nor does it engage in summarizing, humor, or task assignment."
        }
    },
    {
        "utterance": "Molly Bright: Just to put that out there. That's a very different thing and much more interpretable. ",
        "annotations": {
            "offer feedback": "Molly provides her viewpoint on the interpretability of spectroscopy compared to other methods, offering a perspective on the methodologies discussed.",
            "supportive response": "Molly contributes to the discussion by sharing her thoughts, which can be seen as supporting the exploration of different methodologies."
        }
    },
    {
        "utterance": "Alex Walsh: Yeah, I think um, there's a lot of different things you can measure with metabolism, right? And uh, understanding the relationship between the molecules you're detecting and right your physiological outcome that you want to to actually know something about is is an important bridge that needs to be crossed. Um, so like when you do autofluorescence of NADH and FAD, we're very good at finding those molecules, but we're not so great at knowing what that tells us about metabolism. Um, and so I think that's that's the challenge for the field that I work in is trying to be more specific with things like metabolic pathways. ",
        "annotations": {
            "identify gap": "The speaker identifies a gap in understanding the relationship between measured molecules and physiological outcomes.",
            "develop idea": "The speaker elaborates on the challenges of measuring metabolism and the need for specificity in metabolic pathways.",
            "clarify goal": "The speaker discusses the goal of achieving more specificity in understanding metabolic pathways."
        }
    },
    {
        "utterance": "Alex Walsh: So. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Matt Bogyo: Alex, can you expand on the limits of the using the endogenous fluorescence? ",
        "annotations": {
            "ask question": "The utterance is a direct question asking for information or clarification on the limits of using endogenous fluorescence."
        }
    },
    {
        "utterance": "Allison Dennis: So you know how how thick of a tissue can you look at? Is it only monoculture? Can you look at spheroid? Yeah, what what's the scope can you. ",
        "annotations": {
            "ask question": "The speaker is requesting information about the method's capabilities, specifically regarding the thickness of tissue it can analyze and the types of samples (monoculture vs. spheroid) it can handle."
        }
    },
    {
        "utterance": "Alex Walsh: Right. So it's it's just like normal fluorescence. So whatever techniques you use, it's it we can do it too. Um, so so we can do single photon and it's really great at looking at cells on a dish, but we can also adapt it for multiphoton and optical technologies that can do three-dimensional things like organoids or even in vivo up to a couple millimeters. ",
        "annotations": {
            "develop idea": "The speaker is expanding on how fluorescence techniques can be used for various imaging applications, including single-photon and multiphoton technologies.",
            "signal expertise": "The speaker is showing expertise in optical imaging techniques, specifically fluorescence and its applications in biological imaging."
        }
    },
    {
        "utterance": "Matt Bogyo: I guess we should consider checking in with Kevin, seeing how uh how's things looking over there. Kevin, do we should probably pull together as a group and kind of summarize some of the main things we've been discussing so we have a sense of the report out. What do you think? ",
        "annotations": {
            "develop idea": "The speaker suggests summarizing the discussion to move it forward.",
            "ask question": "The speaker asks Kevin for his thoughts.",
            "encourage participation": "The speaker invites Kevin to contribute his opinion.",
            "process management": "The speaker manages the meeting flow by suggesting a summary."
        }
    },
    {
        "utterance": "Kevin Cash: Yeah, it's it's currently quite chaotic. ",
        "annotations": {
            "process management": "The speaker comments on the current chaotic state of the discussion, implying a need for better organization or flow."
        }
    },
    {
        "utterance": "Matt Bogyo: Yeah, it's a little bit all over. Do you have um some notes or do you want to share screen or do you how do you want to do it? ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by asking how to organize the discussion or share information."
        }
    },
    {
        "utterance": "Kevin Cash: Uh yeah, I can share the screen. ",
        "annotations": {
            "process management": "Kevin is offering to share his screen, which is a task related to managing the meeting flow and organization."
        }
    },
    {
        "utterance": "Kevin Cash: So yeah, here's here's what I've got now that from the scattered notes that I've been taking throughout the the session. So I listed some of the targets that we talked about that were good proxies, some general comments on tying it together. ",
        "annotations": {
            "summarize conversation": "Kevin is summarizing his notes from the session, listing targets that were discussed as good proxies and making general comments on tying them together."
        }
    },
    {
        "utterance": "Matt Bogyo: But I think some of the ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Kevin Cash: The things that are worth bringing up like I don't know if it's worth bringing up the challenges of individual modalities to the the whole group when we come back, but some of the discussions about like, okay, amplifying the signal, that seems like a higher value addition to to bring up for discussion with the other groups of because that seems at least to me like a big challenge moving forward is how do we get these low concentration signals that might be more beneficial than just, okay, things like blood flow or things like oxygen. How can we get low concentration things that might be valuable to have a signal big enough to measure. ",
        "annotations": {
            "process management": "The speaker is considering how to manage the discussion or information sharing with the group.",
            "offer feedback": "The speaker is providing suggestions for future discussions or directions, specifically regarding signal amplification and addressing low concentration signals."
        }
    },
    {
        "utterance": "Matt Bogyo: Yeah, I like it. I mean, I think I think having one of our main bullet points or discussion points for the for the for the for the end would be, yeah, these challenges and limitations associated with imaging metabolites in particular. Um, I guess the question is to what I think it's good to break it down to like two or three or maybe four at most kind of main points and then um, pick from the sort of notes you have which look quite quite good. ",
        "annotations": {
            "process management": "The speaker is suggesting how to organize and structure the discussion points for the end of the meeting.",
            "summarize conversation": "The speaker is also summarizing the idea of discussing challenges and limitations associated with imaging metabolites."
        }
    },
    {
        "utterance": "Matt Bogyo: Um what are people's thoughts? ",
        "annotations": {
            "encourage participation": "The speaker invites others in the group to contribute their expertise, opinions, or ideas."
        }
    },
    {
        "utterance": "Katharine White: Yeah, I agree with that and I think this idea of amplification is important for for low abundant metabolites or oncometabolites or disease associated metabolites that might be important diagnostically. But I do think that Allison, I think made a good point about under certain conditions you may want the ability to to look at this dynamically and to look at metabolite production dynamically over a longer cellular process. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by providing additional thoughts on the importance of amplification and dynamic observation of metabolite production.",
            "acknowledge contribution": "The speaker acknowledges Allison's point about the need for dynamic observation under certain conditions.",
            "supportive response": "The speaker is expressing agreement and validation with previous points made."
        }
    },
    {
        "utterance": "Katharine White: Which also has as we've discussed a lot of a lot of potential challenges in terms of being able to do that quantitatively. ",
        "annotations": {
            "develop idea": "The speaker is expanding on previous discussions about challenges in metabolic imaging and quantification.",
            "identify gap": "The speaker is highlighting the challenges in being able to quantify metabolic processes.",
            "offer feedback": "The speaker is providing a perspective on the challenges related to quantification."
        }
    },
    {
        "utterance": "Ping Wang: I I do like a context uh comment on the data like integration because the complexity of the metabolic metabolics uh so process. So um, I I think we should have a one um, one um point uh for the um integrated um data like for the all the uh information from imaging and also uh if you're talking about clinical application other uh features in clinic um for the diagnosis purpose um using um AI or deep learning. Probably we don't have many deep learning people here, nobody mentioned that. ",
        "annotations": {
            "propose new idea": "The speaker introduces the idea of integrating data and using AI or deep learning for clinical applications.",
            "develop idea": "The speaker expands on the need for data integration due to the complexity of metabolic processes.",
            "offer feedback": "The speaker provides a suggestion for approaching data integration and mentions the potential use of AI or deep learning."
        }
    },
    {
        "utterance": "Lingyan Shi: And uh um I think we perhaps can add a bio marker into this uh tool for diagnostic uh purpose because uh for example the amyloid beta protein it has a very specific peak in Raman region, Raman bands. It is separable from other protein. So as long as there is amyloid beta then we can detect it with the specific peak only belong to this molecule. ",
        "annotations": {
            "propose new idea": "The speaker introduces using amyloid beta protein as a biomarker for diagnostic purposes, a new idea.",
            "develop idea": "The speaker elaborates on the idea by explaining the specific peak of amyloid beta protein in Raman region."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): how we balance, you know, different things for different applications. Um, and then talked about complexity of data interpretation, that's one challenges, one of the challenges. Uh, any other um, challenges that people want to mention? Do we want to, I guess Kevin, one one of Kevin's questions is whether we go through the the challenges for individual modality or talk about a few shared or or or common, right? Um, critical challenges for imaging metabolites. ",
        "annotations": {
            "ask question": "The speaker asks for other challenges people want to mention.",
            "process management": "The speaker is managing the discussion flow by considering how to address challenges.",
            "encourage participation": "The speaker invites others to contribute their thoughts."
        }
    },
    {
        "utterance": "Allison Dennis, Boston U (she/her): think given the constraints of the the report out, keeping it to the general challenges, like there's always the challenge of signal to noise and the um, having enough signal for a small concentration analyte. Those things are endemic regardless of your modality. ",
        "annotations": {
            "identify gap": "The speaker is highlighting a challenge in imaging metabolites, which is a gap in capability.",
            "process management": "The speaker is commenting on the report out process and suggesting focusing on general challenges."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Looks like we got about five minutes here, so you may want to start to consolidate and get this onto the slide deck maybe. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by suggesting that the group consolidate their thoughts and prepare a slide deck."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: So what do you guys think is the most important other than the challenges? Like, do you think it's important to share with everyone some of the targets that we discussed? Do you think it's important to share some of these other questions we were talking about of heterogeneity or tying in genetics or focusing on talking about some other approaches? What do you guys think is most valuable for us to report back? ",
        "annotations": {
            "encourage participation": "The speaker is explicitly inviting group members to share their thoughts and opinions.",
            "process management": "The speaker is discussing the process of what to include in their report back."
        }
    },
    {
        "utterance": "Katharine White--Notre Dame: Um, I really liked, I think it was Candace's point about this um having a a genetic fingerprint or metabolomic fingerprint that that you could use diagnostically. Um, there's a lot of work that we need to do in order to, you know, identify the what what that fingerprint looks like um but I think that was a an interesting uh concept that from from our discussion that was exciting to me. ",
        "annotations": {
            "acknowledge contribution": "Katharine White acknowledges Candace Fleischer's previous point about genetic or metabolomic fingerprints for diagnostic use.",
            "supportive response": "Katharine White expresses agreement and finds the concept of a genetic or metabolomic fingerprint for diagnostic use as interesting and exciting."
        }
    },
    {
        "utterance": "Lingyan Shi: ming establish a library for standard compounds that can be a target. ",
        "annotations": {
            "propose new idea": "The utterance introduces a new suggestion for establishing a library of standard compounds that can be a target."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: I think we're going to have to make some decisions here. We got two minutes or three minutes. We're going to be the first ones reporting out. So I I think uh, you know, I don't know, personally, I I can give you my opinion. I think I think that um this giving some overview of the kinds of metabolites that are being reported on, talking about the modalities that we discussed and and then going into the limitations would probably be the most useful information for people, I would say. ",
        "annotations": {
            "process management": "The speaker is suggesting how to structure their report-out, indicating management of their meeting flow.",
            "summarize conversation": "The speaker is summarizing what they have discussed, proposing to cover metabolites, modalities, and limitations in their report-out."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: What did you say for the first part? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification about a prior statement, seeking to understand what was said earlier."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Like talking about the types of um metabolites that are imaged. So you have a nice kind of list there of things that are, you know, what is sort of the cutting edge and what are people looking at and then um I think mentioning the modalities that are used and then the limitations. I think that that was kind of the bulk of a lot of our discussion. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing the main points of previous discussions, outlining what to include in the report-out."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Yeah, that sounds great. ",
        "annotations": {
            "supportive response": "The utterance expresses agreement with a previous statement, which is a positive evaluation or validation of the idea presented."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): So the the first uh bullet point. ",
        "annotations": {
            "process management": "Jin Zhang is managing the discussion flow by referring to specific bullet points."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Yeah, I know. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): and the limitations, right? And the modalities in the need. ",
        "annotations": {
            "supportive response": "The speaker is acknowledging and showing agreement with previous discussion points regarding limitations and modalities."
        }
    },
    {
        "utterance": "Lingyan Shi: I think I have a comments on the the and problem is a question driven or tech technical driven, maybe biological question driven will give us a very clear target molecule, so we can seek the tool easier. Find out which one is the best. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of how to approach the problem of metabolic imaging by suggesting that a biological question-driven approach could be beneficial.",
            "offer feedback": "The speaker is offering a suggestion on how to proceed with choosing an approach for metabolic imaging.",
            "clarify goal": "The speaker is contributing to clarifying the goal by suggesting a question-driven approach."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Yeah, definitely uh we we kind of covered that sort of application based uh considerations, right? ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing that a topic has been covered in the discussion."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Great. Great discussions. Thanks everyone. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Thanks Matt. ",
        "annotations": {
            "acknowledge contribution": "The speaker is verbally recognizing Matt's contribution or effort in leading the discussion."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Yep, thank you. Jen, we'll see you guys in the main room. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lingyan Shi: Thank you. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lingyan Shi: Bye. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lingyan Shi: Thank you, Kevin. ",
        "annotations": {
            "acknowledge contribution": "The speaker verbally recognizes Kevin's input, showing appreciation for his contribution."
        }
    },
    {
        "utterance": "Silvia Ronco, RCSA:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Aniruddha Ray:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    }
]